Mary Jo oversees a talented team analyzing business and clinical activity for Scrip, Pink Sheet and In Vivo. Since starting as a reporter in 2000, Mary Jo has held editor positions across Pink Sheet and the former Pink Sheet DAILY and Pharmaceutical Approvals Monthly, and covered the drug development process from clinical trials to FDA review to approval and launch, as well as keeping track of broad industry trends and the commercial landscape. Mary Jo helped create the FDA Performance Tracker charts as a way to use regulatory data to aid development decisions and better understand agency patterns, and continues to enjoy working with data to identify industry trends through features and infographics. She frequently moderates webinars and panels at conferences. An avid reader, Mary Jo volunteers as a literacy tutor and is on the board of the local library.
Latest from Mary Jo Laffler
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.
AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.